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Michigan has had an ongoing outbreak of endemic Mycobacterium bovis which has been recognized within and sustained by
its free-ranging white-tailed deer population since 1994. Worldwide, organisms within the Mycobacterium tuberculosis complex
have exhibited the ability to develop resistance to antimicrobial agents, resulting in both the multidrug-resistant (MDR) and
extensively drug-resistant (XDR) strains of human tuberculosis. Michigan’s Bovine Tuberculosis Working Group has conducted
active antimicrobial susceptibility testing on wildlife isolates of the endemic M. bovis organism at ﬁve-year intervals to detect any
emerging drug resistance patterns. The results of 33 white-tailed deer origin isolates collected from the 2009 hunting season are
reported here. There continues to be no evidence of any drug resistance except for pyrazinamide resistance. These results are likely
due to the lack ofantibacterial treatment applied to either wildlife or domesticanimalswhich wouldprovide selection pressure for
the development of drug resistance.
1.Introduction
The state of Michigan has had an ongoing free-ranging
white-tailed deer tuberculosis surveillance and control pro-
gram since 1994 [1, 2] .I ta p p e a r st h a td e e rs e r v ea st h e
primaryreservoirhostinthestateofMichigan, withelkanda
varietyof wildcarnivoresand omnivoresserving as spill-over
hosts, and to date there have been 50 cattle herds infected
by M. bovis [3], While some progress has been made on
controlling the spread of M. bovis outside of the endemic 12
countyarea and theoverallincidencerate ofinfection in deer
hasdroppedfromaround 4.9%toapproximately1.7%,there
remain ongoing programs for surveillance, and the ultimate
goal is to eradicate the disease from both domestic cattle and
wild deer [4]. Since M. bovis is also infectious to humans,
a multiagency task force consisting of personnel from state
departments (Michigan Department of Natural Resources
and Environment, Michigan Department of Agriculture,
and Michigan Department of Community Health), from a
public university (Michigan State University), and from a
federal agency (United States Department of Agriculture)
have formed a bovine tuberculosis task force to deal with
issues concerning wildlife, domestic animals, and human
health [1, 2].
Bovine tuberculosis threatens human health through
direct acquisition of the disease from ﬁeld dressing infected
deer,from airborne transmission ofthedisease frominfected
cattle or captive deer, and from ingestion of unpasteurized
milk or undercooked meat products including venison
[5–7]. Over the last sixteen years, only two human cases
have been identiﬁed as associated with the speciﬁc strain
of M. bovis endemic in Michigan deer and cattle [7]. One
case was an elderly individual who was raised on a farm
and may havebeen exposed decadesearlier throughdrinking2 Veterinary Medicine International
unpasteurized milk. A second case was a hunter who cut
his hand while ﬁeld-dressing a deer carcass and developed
a localized cutaneous infection which has been subsequently
treated successfully. Since humans do occasionally become
exposed and infected by this organism, our task force has
instituted regular antimicrobial susceptibility testing of deer
and other wildlife isolates, so that we may recognize any
developing antibacterial resistance [8].
Mycobacterial species in the M. tuberculosis complex
undergo low-frequency spontaneous chromosomal muta-
tions which result in genetic resistance to antituberculosis
drugs. For example, M. tuberculosis undergoes spontaneous
mutations resulting in resistance to isoniazid at a frequency
of 3.5 × 10−6 and mutations resulting in rifampin resistance
at a frequencyof3.1×10
−8 [9].However, it isthe application
of antituberculosis drugs which creates pressure for selection
of these strains with mutations. This is generally due
to improper therapeutic applications such as insuﬃcient
length of drug treatment, poor patient adherence to dosing
schedules, using a single antituberculosis drug instead of the
recommended multiple drug therapy, and failure to recog-
nize pre-existing resistance in a tuberculosis case [10]. These
problems then lead to the emergence of either multidrug-
resistant (MDR) or extensively drug-resistant (XDR) strains
of mycobacteria. MDR is deﬁned as resistant to at least
rifampicinandisoniazid,whichareﬁrst-lineantituberculosis
drugs. XDR is deﬁned by the World Health Organization
Global Task Force on XDR-TB as resistant to rifampicin
and isoniazid, as well as any member of the ﬂuroquinolone
family, and one or more of the second-line antituberculosis
drugs including kanamycin, capreomycin, or amikacin [10].
Fortunately, these forms of antituberculosis drug resistance
are not as prevalent in veterinary medicine as they are in
human medicine because we tend to cull infected animals
rather than treat them for tuberculosis [5].
The objectives for this study were to (1) take the
majority of the 2009 hunter-harvested wild deer isolates of
M. bovis from Michigan and conduct routine antimicrobial
susceptibilitytesting by two diﬀerentmethodologiesin order
to detect any evidence of new antimicrobial resistant strains
and (2) compare the 2009 data with the 1999 and the 2004
antimicrobial studies which utilized similar methods [8].
2.Materialsand Methods
All culture positive deer M. bovis samples submitted to
the Michigan Department of Community Health Tuber-
culosis Laboratory during the 2009 wild white-tailed deer
hunting season were tested for antimicrobial susceptibility.
The antimicrobial agents tested included isoniazid, strep-
tomycin, rifampin, ethambutol, ethionamide, kanamycin,
ciproﬂoxacin, cycloserine, capreomycin, and pyrazinamide.
Isolates from 33 deer were utilized in this study.
2.1. Proportion Plate Method. Isolates were subcultured into
Middlebrook 7H9 broth which was then incubated at 35◦C
for 2 to 6 days. Subcultures were then used to conduct 1%
proportionplatesusceptibilityassaysbypreviously described
methods [11, 12]. Middlebrook 7H10 agar plates were
prepared with 5mL of medium into each of four quadrants
in the Petri dishes, which then had drug-impregnated discs
placed into each quadrant, with one drug-free quadrant
serving as a control. Powdered suspensions were utilized for
t h ec y c l o s e r i n ea n dc a p r e o m y c i n preparations. Final drug
concentrations in these plates were 0.2 and 1.0µg/mL isoni-
azid, 2.0 and 10.0µg/mL streptomycin, 1.0µg/mL rifampin,
5.0µg/mL ethambutol, 5.0µg/mL ethionamide, 6.0µg/mL
kanamycin, 2.0µg/mL ciproﬂoxacin, 30.0µg/mL cycloser-
ine, 10.0µg/mL capreomycin, and 100µg/mL pyrazinamide.
Plates were inoculated to reach a colony count of between
100 and 200 colony forming units on the control quadrant
containing no drug. Plates were incubated as 35◦Cw i t h
CO2 for 3 weeks. Percentage resistance for each drug was
calculated by dividing the total number of colonies in a
quadrant by the total number of colonies in the control
quadrant and multiplying the result by one hundred. A
1% standard cutoﬀ value was used for the interpretation of
resistance. Therefore, a culture with a percent resistance of
less than 1% was considered susceptible to that particular
drug at that concentration while a culture with a percent
resistance greater than or equal to 1% was considered
resistant to that particular drug.
2.2. Bactec Method. Bactec radiometric susceptibility testing
was the second method used to evaluate M. bovis isolates for
antimicrobial resistance and followed previously described
methods [13].The following antimicrobialdrugswere added
to Bactec 12B vials: isoniazid at 0.1g/mL, streptomycin at
2.0g/mL, rifampin at 2.0g/mL, and ethambutol at 2.5g/mL.
A suspension of each isolate was diluted to a 0.5 MacFarland
suspension and then inoculated into vials containing each
of the drugs. A drug-free control vial was also prepared by
diluting the 0.5 MacFarland suspension by 1:100. Vials were
read each day using the Bactec 460 TB instrument until the
growth index (GI) of the control vials reached 30 or greater.
Susceptibilityresults were determined by comparing theΔGI
(diﬀerence between the current day’s GI value with the GI
value from the previous day’s reading) of the drug vial to the
ΔGI of the control vial. A resistant isolate had a ΔGI value
greater than the ΔGI value of the control vial.
The Bactec method for determination of pyrazinamide
was somewhat diﬀerent from the other drugs tested. A 0.5
MacFarland suspension of each isolate was inoculated into a
Bactec 12B vial and then grown out to a GI value of greater
than 300. Next, these vials contents were inoculated into 2
pyrazinamide test medium vials. Pyrazinamide was added to
one vial at a concentration of 100µg/mL while the second
vial served as a drug-free control. Vials were read each day
usingtheBactec460TBinstrumentuntilthecontrolGIvalue
reached greater than or equal to 200. Bactec pyrazinamide
results were interpreted by dividing the GI of the drug vial
by the GI of the control vial and multiplying the result
by 100 to calculate the percentage resistance. Percentage of
resistance less than 9% was interpreted as susceptible to
pyrazinamide while percentage of resistance greater than
11% was interpreted as resistant. Percentages between 9 andVeterinary Medicine International 3
Table 1:AntimicrobialsusceptibilityresultsforMichigandeerfrom
2009.
Host
Species
Bactec
method
Bactec
PZA1 method
Proportion
method
Proportion
method PZA1
Deer 0/332 33/332 0/332 33/332
1PZA: pyrazinamide
2Number of resistant isolates over the total number of isolates tested.
11% were considered equivocal, and repeat of the assay was
performed; this repetition of the assay was rarely needed.
3.Results
For the 2009 deer isolates of M. bovis, all 33 were sus-
ceptible to isoniazid, streptomycin, rifampin, ethambutol,
ethionamide, kanamycin, ciproﬂoxacin, cycloserine, and
capreomycin by the proportion plate method (Table 1). All
33 isolates were also susceptible to isoniazid, streptomycin,
rifampin, and ethambutol by the Bactec method. All 33
isolates were resistant to pyrazinamide (100%) by both the
proportion plate and the Bactec methods. These results
indicating no drug resistance except for pyrazinamide were
identical to our ﬁndings in the 1999 and 2004 surveys, in
which there were 30 deer isolates tested in 1999 and 28 deer
isolates tested in 2004 [8].
4.Discussion
It was expected that all deer M. bovis isolates would be
resistant to pyrazinamide. Historically, M. bovis isolates are
resistant to pyrazinamide because the organism does not
produce the enzyme pyrazinamidase which is needed to
convert pyrazinamide into pyrazinic acid, the active form
of the antimicrobial agent [14]. This resistance is one of
the basic features which can be used to distinguish isolates
of M. bovis (universally resistant to pyrazinamide) from M.
tuberculosis (commonly susceptible).
The fact that no detectable emerging antimicrobial
resistant M. bovis strains were found is good news, especially
for the rare individual who is infected with this M. bovis
strain and must undergo therapy. It is most likely explained
by the fact that wild deer and other wild spill-over hosts
are commonly found to be infected with M. bovis only after
they have been harvested by hunters or trappers. Likewise,
when either domestic cattle or captive cervids in Michigan
are detected as TB suspects or reactors on antemortem
surveillance, they are routinely slaughtered and sent for full
tuberculosis testing which includes culture and PCR assays.
In either circumstance, there is no antibacterial treatment
applied to infected or possibly infected individual animals,
which means there is no selection pressure to favor the
development of drug-resistant strains. Furthermore, the
antimicrobial susceptibility surveys conducted at 50-year
intervals give us a broad overview of resistance development
since the disease was ﬁrst recognized as endemic in Michigan
deer 16 years ago.
Unlike the two previous susceptibility surveys conducted
in 1999 and 2004, this survey was limited to wild deer,
the primary reservoir host of M. bovis in Michigan. This is
due to changes in the processing of tuberculosis surveillance
samples. In earlier years, all wild animal samples including
thespill-overhostscomprised byvariouswild carnivoresand
omnivores, used to run through the state diagnostic labora-
tory and the Tuberculosis Laboratory, Michigan Department
of Community Health. Starting in 2005, personnel from the
Wildlife Services, United Sates Department of Agriculture,
took overtheresponsibility for nondeerwildlife surveillance,
and those samples are shipped to another state for testing.
Likewise, during theearlier years ofthetuberculosisendemic
thesuspectcattlewhichwereprocessedatthestatediagnostic
laboratoryhadduplicatesamplescollectedforculturebothat
the Diagnostic Bacteriology Laboratory, National Veterinary
Services Laboratory (NVSL), Ames, Iowa, as well as at
the local Michigan Department of Community Health
Laboratory. However, in recent years, samples have only
been collected for NVSL, as this is a program disease for
which the USDA has primary authority, and the fact that
duplicate processing was considered redundant and too
expensive for current ﬁscal budgets. Since the wild deer
are considered the principal reservoir host, we feel that the
current antimicrobial susceptibility survey is still valid in
spite of the absence of the other wildlife and domestic cattle
isolates.
While the lack of any detectable antimicrobial resistance
development is good news, there remains reason for caution
and continued regular surveys of this type. In July, 2009,
the USDA, Animal and Plant Health Inspection Service
produced a concept paper for new approaches to managing
bovine tuberculosis which are currently being implemented
[15]. One of their recommendations was to begin apply-
ing whole-herd depopulation judiciously and developing
alternative control strategies including test and cull of
individual suspect animals. This is a reasonable response
to the enormous costs that USDA and state departments
of agriculture must expend in order to depopulate and
indemnify ever larger cattle herds, many with valuable
individual breeding animals. However, we should remember
that the reason why drug-resistant strains of M. bovis are
not emerging in animals nearly as rapidly as in human
populations is because of the lack of treatment-related
selection pressures. No one is suggesting that individual
cattle or captive cervids which are identiﬁed as tuberculosis
suspects should start to receive antimicrobial therapy as
we do with infected people. When whole-herd test and
individual animal culling practices are employed, there is
the very real opportunity for other animals in the same
herd which may be harboring tuberculosis to receive limited
antibacterialtherapyforotherconditions,suchasrespiratory
disease, mastitis, or other localized infections. Alternatively,
whole beef cattle herds may be treated with long-term low-
level antibacterial agents as growth promoters. In this type
of environment, asymptomatic and undetected tuberculosis
carriers will be subjected to similar selection pressures that
have produced the current worldwide emergence of MDR
and XDR tuberculosis strains in humans. This is not meant4 Veterinary Medicine International
to ﬁnd fault with newer management procedures for bovine
tuberculosis but only to point out that selection pressures
which promote antimicrobial resistance development may
wellbeincreasing,atleastinourdomesticandcaptiveanimal
species. Therefore, continued surveillance for drug-resistant
strains of M. bovis will be even more important as we move
forward to ensure the safety of our milk, beef, and venison
sources for human consumption.
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